Gelita AG has established a centre for biotechnology. At the Biotech Hub in Frankfurt am Main/Germany, biologists and biotechnologists work, among other things, on the development of proteins from biotechnological processes for applications in nutrition, cosmetics, and pharmaceutical and medical products. The investment in the new site represents a milestone for the company on its way to a broader, sustainable product portfolio.

“Investing in Gelila’s Biotech Hub is a clear commitment to biotechnology, a key and future-oriented 21st-century technology that offers enormous innovation potential,” said Dr Sven Abend, CEO of Gelita, at the opening ceremony. “It allows us to meet the growing demand of international markets sustainably and with new offers. At the same time, the new research laboratory underlines our commitment to innovation in our markets and our goal of sustainable, profitable growth.”

Gelita collagen peptides from animal raw materials have recorded high growth rates in recent years. As a pioneer in the clinical research and production of specific bioactive collagen peptides, the company also plans to systematically expand its expertise in the field of biotechnology. A move that shall secure its core business in the long term and open up new, lucrative market segments.

In the new research laboratory located in the Höchst Industrial Park in Frankfurt am Main, Laboratory Manager Dr Christoph Schorsch and his team are developing and optimizing microorganisms that can produce almost unlimited varieties of organic compounds. Their initial focus is on proteins for the food and cosmetics industries and companies in the pharmaceutical and medical sectors.